Cancer Letters
Volume 238, Issue 2 , Pages 197-201, 18 July 2006

Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model

  • Miaorong She

      Affiliations

    • Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • Dr. M. She is a visiting scholar from the Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, People's Republic of China.
    • ,
  • Sai-Ching Jim Yeung

      Affiliations

    • Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Address: The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 437, Houston, TX 77030, USA. Tel.: +1 713 745 4516.

Received 30 October 2004; accepted 5 July 2005.

Abstract 

We previously showed that the in vivo anticancer effects of a combination of manumycin (a farnesyltransferase inhibitor) and paclitaxel (a microtubule inhibitor) against anaplastic thyroid carcinoma (ATC) were partially due to inhibition of angiogenesis. In this study, we investigated the effect of adding minocycline (a matrix metalloproteinase inhibitor) to manumycin and paclitaxel against human ATC cells xenografted in nude mice. The triple-drug combination resulted in the lowest average tumor growth rate, and it conferred significantly better survival than manumycin alone, paclitaxel alone, or manumycin plus paclitaxel. In conclusion, this novel combination deserves further investigation in the treatment of ATC.

Keywords: Manumycin, Paclitaxel, Minocycline, Human anaplastic thyroid carcinoma, Nude mouse xenograft model, Angiogenesis inhibition

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(05)00671-3

doi:10.1016/j.canlet.2005.07.012

Cancer Letters
Volume 238, Issue 2 , Pages 197-201, 18 July 2006

Article Tools

* Image Usage & Resolution